ARCUTIS BIOTHERAPEUTICS, INC. Interest Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Interest Expense of $7.48 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-14
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $7.48M, a 6.22% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was $7.76M, a 12.25% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $7.56M, a 54.30% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2023-06-30 was $7.35M, a 267.45% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for fiscal 2023 was $29.71M, a 89.83% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for fiscal 2022 was $15.65M.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for fiscal 2021 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense for fiscal 2020 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.48M 10-Q · filed 2024-05-14 | $15.24M derived: sum of 2 quarters · filed 2024-05-14 | $22.80M derived: sum of 3 quarters · filed 2024-05-14 | $30.15M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | $7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $15.32M derived: sum of 2 quarters · filed 2024-02-27 | $22.67M derived: sum of 3 quarters · filed 2024-02-27 | $29.71M 10-K · filed 2024-02-27 |
| 2023-09-30 | $7.56M 10-Q · filed 2023-11-03 | $14.91M derived: sum of 2 quarters · filed 2023-11-03 | $21.95M 10-Q · filed 2023-11-03 | $28.86M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-06-30 | $7.35M 10-Q · filed 2023-08-08 | $14.39M 10-Q · filed 2023-08-08 | $21.31M derived: sum of 3 quarters · filed 2024-05-14 | $26.20M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | $7.04M 10-Q · filed 2024-05-14 | $13.96M derived: sum of 2 quarters · filed 2024-05-14 | $18.86M derived: sum of 3 quarters · filed 2024-05-14 | $20.86M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $11.81M derived: sum of 2 quarters · filed 2024-02-27 | $13.81M derived: sum of 3 quarters · filed 2024-02-27 | $15.65M 10-K · filed 2024-02-27 |
| 2022-09-30 | $4.90M 10-Q · filed 2023-11-03 | $6.90M derived: sum of 2 quarters · filed 2023-11-03 | $8.74M 10-Q · filed 2023-11-03 | $8.74M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.00M 10-Q · filed 2023-08-08 | $3.84M 10-Q · filed 2023-08-08 | $3.84M derived: sum of 3 quarters · filed 2024-02-27 | $3.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.84M 10-Q · filed 2023-05-09 | $1.84M derived: sum of 2 quarters · filed 2024-02-27 | $1.84M derived: sum of 3 quarters · filed 2024-02-27 | $1.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |